ADAP

To see the most recent ADAP Waiting List Update

The AIDS Drug Assistance Program (ADAP) is a discretionarily funded program established through Part B of the Ryan White C.A.R.E. Act. It is designed as a payer of last resort to supply necessary antiretroviral (ARV) medications to low income, uninsured or underinsured HIV infected individuals. The nation's ADAPs provide service in all 50 states, Washington D.C., and the US territories. As well as supplying the life saving ARVs, ADAP also assists with necessary supplemental medications that counteract the debilitating side effects caused by HIV/AIDS treatment. Please see the below resources for more information.

Funding for HIV/AIDS drugs was started in the late 1980s to address the emerging health crisis associated with the Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS). ADAP was incorporated into the Ryan White CARE Act when it was first signed into law as a joint venture between the federal and state governments. In the beginning of the program, federal funding accounted for approximately 75% of the costs while states were accountable for the remainder. Since then, ADAP has gone through a series of changers during the course of its reauthorizations. Currently the federal share is just under 50% of the program, states are contributing 21%, and pharmaceutical rebates and initiatives supply the remainder of the ADAP need. The progressive decrease in the amount of funding supplied by the federal government has caused cost containment measures and waiting lists to be implemented. Click here to learn about the ADAP wait list see the most current ADAP waiting list numbers.

For full National ADAP Monitoring Project Annual Reports see the Kaiser Family Foundation Website